alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–41 of 41 studies with an author at University of Kansas (US) (page 2 of 2) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 41 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Validation of Wellbeing Scales Among Informal Caregivers of Latinos With Alzheimer’s Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Hispanic Journal of Behavioral Sciences 2025-01-10

All concurrent validity correlations followed the expected directionality, with 19/21 inter-scale correlations in the total sample reaching statistical significance (p<0.05), and 17/21 reaching at least a low correlation (0.3). 4 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-functional role of apolipoprotein E in neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Aging Neuroscience 2025-01-29

Genetic diversity in the apolipoprotein E (ApoE) gene has been identified as the major susceptibility genetic risk factor for sporadic Alzheimer’s disease (SAD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Biochimica et biophysica acta 2011-10-12

There has been no extensive characterization of the effects of Ginsenoside Rg1, a pharmacological active component purified from the nature product ginseng, in an Alzheimer's disease mouse model. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Presenilin-1 Familial Alzheimer Mutations Impair γ-Secretase Cleavage of APP Through Stabilized Enzyme–Substrate Complex Formation

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Biomolecules 2025-07-01

Familial Alzheimer's disease (FAD) is caused by dominant missense mutations in amyloid precursor protein (APP) and presenilin-1 (PSEN1), the catalytic component of γ-secretase that generates amyloid β-peptides (Aβ) from the APP C-terminal fragment C99. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multilevel and Multidimensional Features of Socioeconomic Status and Cognitive Function in Older Adulthood: Findings from the IGNITE Study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-12-01

Lower objective SES was associated with poorer performance on all cognitive domains: episodic memory (β = 0.115, p = 0.003), executive function (β = 0.210, p 0.05). 5 key findings →

Design: cross-sectional Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A scoping review of interventions for Hispanic caregivers of persons living with dementia

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2025-10-21

Dementia disproportionately affects Hispanic/Latino caregivers, and while some interventions exist, their consideration of intersectional factors remains unclear. 1 key finding →

Participants: 41 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production

✓ Peer-reviewed alzhub usefulness score 39 out of 100. eLife 2025-02-11

Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer’s disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rural practitioners' experiences in dementia diagnosis and treatment

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Aging & mental health 2004-09-01

When diagnosis of dementia occurs earlier in the disease process, more time is available for treatment aimed at maintaining patient function and delaying decline, and for family education about the disease and its management. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Journal of autism and developmental disorders 2007-01-13

This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

7 FDA Approved CSF Biomarkers Demonstrate Strong Predictive Value for Identification of Alzheimer Disease Based on PET Scan in Patients with Standalone Alzheimer Cognitive Screening Tests

✓ Peer-reviewed alzhub usefulness score 34 out of 100. American Journal of Clinical Pathology 2025-11-01

CSF pTau181/Ab42 ratio is a diagnostic marker for Alzheimer disease correlated well with PET scan compared to various standalone cognitive screening assessment. 5 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-27

Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimers disease (AD), yet their relationship with neurodegeneration remain poorly characterized. 2 key findings →

Participants: 1,756 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Metabolome as a Readout for Adverse Social Exposome Influences on Human Health - A Roadmap for Modifiable Factors and Proactive Health

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2026-02-12

The exposome factors, such as diet, lifestyle, microbiome, chemical exposures and social exposome, shapes human health beyond genetic influences, but the mechanisms remain only partially understood. 1 key finding →

Participants: 449 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed